Poster Sessions

Poster Session A: Friday, September 28, 2018 11:30 AM- 1:00 PM and 5:15 PM- 6:15 PM
Poster Session B: Saturday, September 29, 2018 7:00 AM- 8:00 AM and 11:30 AM- 1:00 PM 

Poster Session A: Big Data Studies; Projects Relating to Equity, Value, and Policy

Posters by Topic

Changing Landscape of Provider Organizations: Poster Boards E3-E9
Guideline Concordant Care Initiatives: Poster Boards E10-G3
Health Disparities: Poster Boards C1-C2, G4-H8
Human Factors Engineering, Information Technology, and Patient Safety: Poster Board B8
Integrating Non-oncology Clinicians into Care Delivery: Poster Boards H9-J2
Integrating Patient Experience Assessment and Patient Reported Outcomes into Practice: Poster Boards B11-B12
Measuring Value and Costs: Poster Boards B9, J3-L5
Payment and Insurance Reform: Poster Boards L6-L11
Specialty and Manpower Issues: Poster Boards L12-M2
Studies that Involve New Combinations of Databases: Poster Boards C3-C8
Studies Using Existing Registries or Databases: Poster Boards B10, C9-E2
Team-based Approaches to Optimizing Care Delivery: Poster Boards M3-P11
Use of Clinical Pathways: Poster Board B7

BOARD B7
Abstract 269: Reducing opioid utilization after urologic oncology surgery.
First Author: Kerri Stevenson, NP


BOARD B8
Abstract 230: Opioid-associated deaths in patients with cancer: A population study of the opioid epidemic over the past 10 years.
First Author: Fumiko Chino, MD, BA


BOARD B9
Abstract 30: Practice transformation: Early impact of OCM on hospital admissions.
First Author: Molly Mendenhall, BSN, RN


BOARD B10
Abstract 1: National trends in admissions for potentially preventable conditions among patients with metastatic solid tumors, 2004-2014.
First Author: Robert Daly, MD, MBA


BOARD B11
Abstract 157: A tale of 2,000 charts: Measuring provider response to patient-reported outcome measures.
First Author: Gillian Hurwitz, MPH


BOARD B12
Abstract 158: Methods for alerting clinicians to concerning symptom questionnaire responses during cancer care: Approaches from two randomized trials (STAR, AFT-39 PRO-TECT).
First Author: Angela Stover, PhD


BOARD C1
Abstract 34: Performance on cancer quality measures: Ethnicity, insurance, and census division disparities.
First Author: Amanda Browner, MS


BOARD C2
Abstract 35: Annual colorectal cancer screening in rural community clinics using the fecal immunochemical test (FIT): Second and third year screening.
First Author: Connie Arnold, PhD


BOARD C3
Abstract 3: National trends in end of life care for veterans with advanced cancer.
First Author: Claire Smith, M.D.


BOARD C4
Abstract 4: Building a novel near real-time multisource database to assess and improve infusion wait time at a comprehensive cancer center.
First Author: Jing Jing Yakowec, MPH


BOARD C5
Abstract 5: External validation of a screening instrument to identify cardiometabolic predictors of mortality in individuals with cancer.
First Author: Bogda Koczwara, MD


BOARD C6
Abstract 6: Predicting acute care use following the initiation of systemic therapy for solid tumors.
First Author: Robert Grant, MA, MD


BOARD C7
Abstract 7: Burdensome transitions on cancer decedents treated in different health care systems at the end of life.
First Author: Risha Gidwani


BOARD C8
Abstract 8: Prognostic value of patient-reported outcomes (PROs) in advanced cancer.
First Author: Shiven Patel, MD


BOARD C9
Abstract 9: Understanding epidermal growth factor receptor mutation (EGFRm) testing in patients (pts) with non-small cell lung cancer (NSCLC) in a large community oncology network.
First Author: Eric Nadler


BOARD C10
Abstract 10: Real-world antiemetic utilization in patients undergoing carboplatin chemotherapy.
First Author: Michael Polson, PharmD, MS


BOARD C11
Abstract 11: Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).
First Author: Anuj Patel, MD


BOARD C12
Abstract 12: Use of myelosuppressive chemotherapy and colony-stimulating factor (CSF) prophylaxis: A longitudinal assessment of practices participating in the Centers for Medicare and Medicaid Services (CMS) oncology care model (OCM).
First Author: Derek Weycker, Ph.D.


BOARD C13
Abstract 13: Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK+) non–small cell lung cancer (NSCLC) receiving second-line ALK inhibitors.
First Author: Huamao Lin, PhD


BOARD C14
Abstract 14: Examining the relative influence of multimorbidity on variations in older cancer patients’ experiences with care.
First Author: Erin Kent, PhD


BOARD D1
Abstract 15: Undertreated pain: Trends over time for older adults with and without cancer.
First Author: Carolyn Presley, MD


BOARD D2
Abstract 16: Quality of care during active surveillance in low-risk prostate cancer patients: A population-based approach.
First Author: Narhari Timilshina


BOARD D3
Abstract 17: The effect of facility volume on treatment guideline compliance and overall survival in oral tongue squamous cell carcinoma.
First Author: Samantha Tam, MD MPH


BOARD D4
Abstract 18: Impact of radiotherapy facility volume on the management and survival of patients with muscle-invasive bladder cancer receiving bladder-preserving therapy.
First Author: Kevin D'Rummo, MD


BOARD D5
Abstract 19: Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy.
First Author: Dylan Zylla, MD


BOARD D6
Abstract 20: Feasibility of cancer clinical trial enrollment goals based on cancer incidence.
First Author: George Tran


BOARD D7
Abstract 21: National patient experience data and correlation with in-hospital adverse gynecologic cancer surgical outcomes.
First Author: Joseph Dottino, MD


BOARD D8
Abstract 22: Utilization of care at the end of life in Medicare decedents with advanced cancer.
First Author: Audrey Wallace, MD


BOARD D9
Abstract 23: Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.
First Author: Lauren Wilson, PhD


BOARD D10
Abstract 24: Triple-negative breast cancer treatment pattern and factors associated with its treatment in the United States: A population study using Central Cancer Registry data, 2013-2015.
First Author: Manxia Wu, MD, MPH


BOARD D11
Abstract 25: Identifying potentially preventable emergency department (PPED) visits among patients with cancer in Ontario.
First Author: Jane Yao


BOARD D12
Abstract 26: Trends in aggressive inpatient care at the end-of-life for stage IV lung cancer patients.
First Author: Chebli Mrad, MD


BOARD D13
Abstract 27: Representativeness of oncology clinical trials in Alberta.
First Author: Safiya Karim, MD


BOARD E1
Abstract 28: Hospital variation in outcomes after surgery for prostate cancer.
First Author: Michael Hassett, MD, MPH


BOARD E3
Abstract 38: Supportive measures to enhance clinical trial data management in oncology community network practices.
First Author: Elizabeth Johnson, MS-CRM, BSN


BOARD E4
Abstract 39: Expansion of high-quality specialized services: The gynecologic oncology experience in Ontario hospitals.
First Author: Julie Gilbert, PhD


BOARD E5
Abstract 40: Tiers of service: Outpatient medical oncology services for British Columbia, Canada.
First Author: Shallen Letwin, BSc Pharm and Pharm.D.


BOARD E6
Abstract 41: Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada.
First Author: Maureen Trudeau, MD, MA, FRCPC


BOARD E7
Abstract 42: A descriptive analysis of clinician input and feedback into the CADTH pan-Canadian Oncology Drug Review process.
First Author: Maureen Trudeau, MD, MA, FRCPC


BOARD E9
Abstract 44: Impact of nontreatment oncology research trials on physician engagement in clinical research in an oncology community practice setting.
First Author: Susan Night, JD, LLM


BOARD E10
Abstract 45: Using standardized electronic pathology data to identify practice variation, potential impact to patient outcomes, and quality improvement initiatives.
First Author: Jessica Kitchen, MSc


BOARD E11
Abstract 46: Real-world genetic testing patterns in metastatic colorectal cancer: Balancing adoption challenges with performance efficiency.
First Author: Adrianne Casebeer, PhD, MS


BOARD E12
Abstract 47: Institutional adherence to National Comprehensive Cancer Network (NCCN) guidelines in neoadjuvant treatment of breast cancer and its correlation to outcomes.
First Author: Raju Vaddepally, MBBS, MD


BOARD F1
Abstract 48: A nonrandomized study on compliance with IDSA guidelines on the choice and dosing of empiric antibiotics for patients with febrile neutropenia after implementation of a new Computerized Physician Order Entry (CPOE).
First Author: Kapil Meleveedu, MBBS, MD


BOARD F2
Abstract 49: Improving quality of cancer survivorship care: From framework to action.
First Author: Larissa Nekhlyudov, MD, MPH


BOARD F3
Abstract 50: Implementation of a multifaceted program to improve uptake of guideline recommendations for adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
First Author: Erin Hahn, PhD, MPH


BOARD F4
Abstract 51: Patterns in breast cancer staging imaging: Are we choosing wisely?
First Author: Brett Barlow


BOARD F5
Abstract 52: Utility and factors associated with imaging early-stage breast cancer: Are we choosing wisely?
First Author: Ana Velazquez Manana, MD, MS


BOARD F6
Abstract 53: Improving radiotherapy quality of care: Examining practice patterns in regional centers.
First Author: Jordan Stosky, MD


BOARD F7
Abstract 54: Pathology quality improvement in British Columbia using performance measurement and knowledge mobilization.
First Author: Nick van der Westhuizen, MB ChB FRCPC


BOARD F8
Abstract 55: Enhanced compliance with appropriate antiemetic prescribing guidelines by utilizing a medically integrated pharmacy antiemetic therapeutic interchange protocol.
First Author: Lalan Wilfong, MD


BOARD F9
Abstract 56: Implementing an EHR guideline–based intervention in paper ordering systems.
First Author: Ari Bell-Brown, MPH


BOARD F10
Abstract 57: From A to Xeloda: Practical considerations for implementing a chemotherapy regimen ordering system intervention.
First Author: Kathryn Egan


BOARD F11
Abstract 58: Performance of community-based lung cancer screening program in a region with a high rate of endemic histoplasmosis.
First Author: Shruti Bhandari


BOARD F12
Abstract 59: Utilization of a web-based supportive oncology training curriculum for healthcare professionals (HCPs).
First Author: Shelly Lo, MD


BOARD G1
Abstract 60: Impact of clinic characteristics on the adoption of a guideline-based standing order algorithm and patient accrual in the pragmatic cluster-randomized trial SWOG S1415CD (NCT02728596).
First Author: Kate Watabayashi, BA


BOARD G2
Abstract 61: Evaluation of the impact of a multidisciplinary intervention to increase pneumococcal vaccination rates in patients with advanced lung cancer.
First Author: Leila Rostamnjad, PharmD


BOARD G3
Abstract 62: Timing of adjuvant chemotherapy administration for early breast cancer.
First Author: Andrew Salner, MD


BOARD G4
Abstract 63: Referral rates and supportive care metrics for a first-year community oncology AYA program.
First Author: Elizabeth Cull, MD


BOARD G5
Abstract 64: Implementation of a fellow-initiated financial toxicity screening tool in medical oncology clinics.
First Author: Samuel Brondfield


BOARD G6
Abstract 65: Feasibility of a patient-reported outcomes quality-of-life instrument to improve care in underserved, ethnic minority patients with cancer.
First Author: Nandita Khera, MD


BOARD G7
Abstract 66: Using a pedigree-based questionnaire to improve efficiency in a general oncology genetics clinic.
First Author: Joshua Gulvin, MD


BOARD G8
Abstract 67: Harnessing AI for health equity in oncology research and practice.
First Author: Alexandra Urman, MPH


BOARD G9
Abstract 68: Cancer history, health insurance coverage, and cost-related medication nonadherence and medication cost-coping strategies in the United States.
First Author: Jingxuan Zhao, MPH


BOARD G10
Abstract 69: A focus on culturally sensitive communication to transform institutional awareness of health care disparities.
First Author: William Maples, MD


BOARD G11
Abstract 70: A review of oncologic therapeutic phase III clinical trial literature: Exploring the reporting of clinical trial data of older patients with cancer.
First Author: Karlynn BrintzenhofeSzoc, PhD, MSW


BOARD G12
Abstract 71: Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich, MD


BOARD H1
Abstract 72: A qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina.
First Author: Emily Ray, MPH, MD


BOARD H2
Abstract 73: Underutilization of GnRH analogues (G) and exemestane (E) in young patients with early-stage breast cancer (BC) in Ontario.
First Author: James Keech


BOARD H3
Abstract 74: Reducing the impact of distance on hematopoietic cell therapy patients.
First Author: Diane Burns, BSc, MSc


BOARD H4
Abstract 75: Comparing quality of care for Medicaid and commercially insured patients with cancer in Washington State.
First Author: Catherine Fedorenko


BOARD H5
Abstract 76: Financial toxicity of cancer treatment at a diverse county hospital.
First Author: Divya Ahuja Parikh, MD


BOARD H6
Abstract 77: Assessment of language needs and resource use among Canadian immigrant patients with cancer.
First Author: Sophia Liu


BOARD H7
Abstract 78: Using ASCO QOPI and the QTP as an improvement model in a small safety net cancer center.
First Author: Crystal Simmons, BS


BOARD H8
Abstract 79: Providing oncologic care with access to clinical trials to an underserved and minority population: The Mayo Clinic/Indian Health Service experience.
First Author: Donald Northfelt, MD, FACP


BOARD H9
Abstract 80: Opportunities for improving cancer care management through primary care-oncology relationships.
First Author: Jennifer Tsui, PhD, MPH


BOARD H10
Abstract 81: Feasibility of medication coordination with lay navigators in outpatient oncology clinics
First Author: Katherine Morgan, PharmD


BOARD J1
Abstract 82: Safety of delivering chemotherapy by community nursing staff supervised by telemedicine in remote New South Wales (NSW).
First Author: Florian Honeyball, MBBS


BOARD J2
Abstract 83: Integrating mental health professionals into the care team to better recognize and manage delirium in hospitalized oncology patients.
First Author: Joseph Hooley, MBA


BOARD J3
Abstract 84: Valued outcomes in the cancer experience: Patient priorities and control.
First Author: Alexandra Zaleta, PhD


BOARD J4
Abstract 85: Real-world comparison of biosimilar filgrastim and reference filgrastim in cancer patients receiving chemotherapy.
First Author: Xiaoxue Chen


BOARD J5
Abstract 86: Understanding the value of clinical survivorship programs.
First Author: Katherine Gilmore, MPH, BA


BOARD J6
Abstract 87: The impact of financial toxicity on quality of life in older patients with cancer: Baseline data from the University of Rochester NCI Community Oncology Research Program (NCORP).
First Author: Asad Arastu, MSc


BOARD J7
Abstract 88: Cost of care for patients with metastatic castration-resistant prostate cancer initiating on docetaxel versus oral targeted therapies in the United States.
First Author: Bingcao Wu


BOARD J8
Abstract 89: Assessment of health care resource utilization (HRU) in patients with castration-resistant prostate cancer (CRPC).
First Author: Sophia Li


BOARD J9
Abstract 90: Experience of financial toxicity among gynecologic oncology patients.
First Author: Sara Bouberhan, MD


BOARD J10
Abstract 91: Uncovering oncologists’ gaps and attitudes toward biosimilars: Impact of a two-phase educational program.
First Author: Zachary Schwartz, MSc, ELS


BOARD J11
Abstract 92: Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.
First Author: Feng Lin


BOARD J12
Abstract 93: Tracking the clinical experience of women with metastatic breast cancer at an academic cancer center.
First Author: Stacey Ingram, MEd


BOARD K1
Abstract 94: Inclusion of health-related quality-of-life data in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
First Author: Adam Raymakers, PhD


BOARD K2
Abstract 95: What factors are associated with oncologist discussions of the costs of genomic testing and related treatment?
First Author: K Yabroff, PhD


BOARD K3
Abstract 96: Measuring the financial stresses of childhood cancer and survivorship.
First Author: George Dahlman


BOARD K4
Abstract 97: Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?
First Author: Andrea Sitlinger, MD


BOARD K5
Abstract 98: Survival gains in multiple myeloma from 2003 to 2014.
First Author: Rafael Fonseca, MD


BOARD K6
Abstract 99: Imaging progression-free survival: How much does it matter to patients?
First Author: Jennifer O'Donnell


BOARD K7
Abstract 100: How nonrandomized trials (NRT) inform pan-Canadian Oncology Drug Review (pCODR) expert review committee (pERC) recommendations in blood cancer.
First Author: Missale Tiruneh


BOARD K8
Abstract 101: Active identification of patients appropriate for palliative care: Impact on use of palliative care and home care resources.
First Author: Nicole Mittmann, PhD


BOARD K9
Abstract 102: Impact of Oncology Care Model (OCM) on episode costs and performance revenues: Considerations for oncology practices.
First Author: Rahul Shenolikar, PhD


BOARD K10
Abstract 103: Impact of novel chronic lymphocytic leukemia drugs on public spending.
First Author: Elena Mow


BOARD K11
Abstract 104: Washington State Community Cancer Care Report: Implications for value-based purchasing.
First Author: Laura Panattoni, PhD


BOARD K12
Abstract 105: Lessons from Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report.
First Author: Laura Panattoni, PhD


BOARD L1
Abstract 106: Deploying end-of-life utilization measures for oncology patients to assess hospital care quality and value.
First Author: Kristen McNiff, MPH


BOARD L2
Abstract 107: An evaluation of shifting administration of high-cost chemotherapy from the inpatient to an outpatient setting.
First Author: David Crosby, PharmD


BOARD L3
Abstract 108: The quality of breast cancer quality measures.
First Author: Whitney Lane, MD


BOARD L4
Abstract 109: Cost-effectiveness analysis of pembrolizumab in cancer therapy: A systematic review.
First Author: Claudette Donatien, PharmD


BOARD L5
Abstract 110: Transition of dose-adjusted EPOCH therapy into the outpatient healthcare setting: Quality and cost considerations for outpatient treatment.
First Author: Ali McBride, PharmD, MS, BCOP, FAzPA


BOARD L6
Abstract 111: Education, engagement, and MIPS: The new era of accountability.
First Author: Diane Denny, DBA


BOARD L7
Abstract 112: Variations in hospitalization and emergency department or observation (ED/OB) stays using the oncology care model (OCM) methodology in Medicare data.
First Author: Shuling Li, PhD


BOARD L8
Abstract 113: Hospitalization and hospital discharge destinations after chemotherapy: Using the Oncology Care Model (OCM) methodology in 2012–2015 Medicare data.
First Author: Yi Peng


BOARD L9
Abstract 114: Health system stakeholder perceptions of financial assistance programs at a comprehensive cancer center.
First Author: Jennifer Spencer, MSPH


BOARD L10
Abstract 115: The challenges of implementing the CMS oncology care model (OCM) in a large multi-center community oncology practice.
First Author: John Brown


BOARD L11
Abstract 116: The impact of value-based payment on the referral of oncology patients to tobacco cessation services.
First Author: Louise Bedard, MBA, MSN


BOARD L12
Abstract 117: Changes in lung cancer screening knowledge, beliefs, and practices among health care providers.
First Author: Louise Henderson, PhD


BOARD M1
Abstract 118: Clinical work intensity among medical oncologists.
First Author: Matthew Hudson, Ph.D., M.P.H.


BOARD M2
Abstract 119: Training staff in a virtual unit.
First Author: Traci Rawlinson, MSN


BOARD M3
Abstract 120: Decreasing initiation of chemotherapy time in elective patients admitted to an inpatient hematology malignancy unit.
First Author: Jose Galeas, MD


BOARD M4
Abstract 121: Impact of a comprehensive copay assistance and drug recovery system in a community cancer center.
First Author: Robert Siegel, MD


BOARD M5
Abstract 122: Quality assessment of tumor boards across an academic and community cancer network.
First Author: Daniel Roberts, MD


BOARD M6
Abstract 123: Reducing infusion wait time: An initiative to increase early signing of medication orders by providers at a comprehensive cancer center.
First Author: Jing Jing Yakowec, MPH


BOARD M7
Abstract 124: Development of a financial navigation program to ease the burden of financial toxicity.
First Author: Melissa Monak


BOARD M9
Abstract 126: Sustaining positive outcomes with a progressive upright mobility program protocol in cancer patients.
First Author: Paul Gehringer


BOARD M10
Abstract 127: Chemotherapy wait times in a network of pediatric oncology clinics.
First Author: Carolyn Russo, MD


BOARD M11
Abstract 128: Creating value: Institution of outpatient infusional EPOCH-based chemotherapy at a safety-net hospital.
First Author: Arjun Gupta, MBBS


BOARD M12
Abstract 129: Reducing infusion wait time: Redesigning medication order verification workflow at a comprehensive cancer center.
First Author: Michael Kearney, MBA


BOARD M13
Abstract 130: Advanced care planning and selection of therapy: Influence on hospitalization for patients with metastatic lung cancer.
First Author: Dana Drzayich Jankus


BOARD N1
Abstract 131: Flu fighters: Flu vaccine administrations in pediatric hematology oncology patients.
First Author: Mehgan Beverley, MS


BOARD N2
Abstract 132: Responding to the opioid crisis in a manner that respects oncology patients: A single institution experience writing policy to promote safe opioid use.
First Author: Cristina Cellurale, MD, PhD


BOARD N3
Abstract 133: Efficacy of an antiemetic therapeutic interchange protocol driven by a medically integrated pharmacy.
First Author: Lalan Wilfong, MD


BOARD N4
Abstract 134: Navigation models in diverse outpatient settings: Shared themes, challenges, and opportunities.
First Author: Narcessa Greenwood, MSN, RN, OCN, CNN-CG


BOARD N5
Abstract 135: A physical assessment tool to evaluate functional status compared to ECOG scores in cancer outpatients.
First Author: Catherine Crandell, PT, DPT, MDiv,


BOARD N6
Abstract 136: Identifying delays in care for patients with NSCLC using value-stream mapping.
First Author: Chad Cummings, MBA


BOARD N7
Abstract 137: Implementing prehabilitation as part of enhanced recovery after surgery (ERAS) efforts at a comprehensive cancer center: A team-based approach.
First Author: An Ngo-Huang, DO


BOARD N8
Abstract 138: Optimizing the use of trimethoprim-sulfamethoxazole for prevention of PCP and opportunistic infections in allogeneic hematopoietic cell transplant recipients.
First Author: Emily Baneman, MD


BOARD N9
Abstract 139: Strategies supporting reduced hospitalization rates in a successful OCM practice.
First Author: Molly Mendenhall, BSN, RN


BOARD N10
Abstract 140: Medically integrated pharmacy: A team-based approach to improve oral oncolytic therapy for cancer patients.
First Author: Gurjyot Doshi, MD


BOARD N11
Abstract 141: The Employers Centers of Excellence in Cancer Care: A collaboration of employers and providers to improve cancer care.
First Author: Manali Patel, MD


BOARD N12
Abstract 142: Introducing enhanced navigation and supportive care into the curative treatment of cancer (SCOOP pathway).
First Author: Christopher Koprowski, MD, MBA


BOARD N13
Abstract 143: Development of a nutrition-focused quality improvement program for new patients with cancer seen at the UTSW Simmons Comprehensive Cancer Center (SCCC) outpatient gastrointestinal (GI) oncology clinic.
First Author: Timothy Brown, MD


BOARD N14
Abstract 144: Assessing the appropriate utilization of the palliative care service by the Carol and Ray Neag Comprehensive Cancer Center at UConn Health.
First Author: Trena Stoute, MBBS


BOARD P2
Abstract 146: Cancer survivorship care plans time and effort.
First Author: Megan Begnoche, MSN, RN, AOCN


BOARD P3
Abstract 147: Addressing advance directive completion rates on an inpatient oncology unit.
First Author: Susan McInnes, MD


BOARD P4
Abstract 148: Improving support for smoking cessation in medical oncology patients: A quality improvement initiative.
First Author: William Raskin, MD


BOARD P5
Abstract 149: Implementation of a regional structure across an oncology collaborative quality initiative and the impact on physician engagement.
First Author: Samkeliso Beusterien, MS


BOARD P6
Abstract 150: Pharmacy contributions to improving care and sustaining change in a comprehensive cancer center.
First Author: Megan Brown, PharmD


BOARD P7
Abstract 151: Assessment of scheduled pharmacy follow-up for patients receiving oral chemotherapy.
First Author: Emily Mackler, PharmD


BOARD P8
Abstract 152: Creation and implementation of a chief fellow of quality improvement in an oncology fellowship program.
First Author: Amy Jones, MD


BOARD P9
Abstract 153: Examining patient burden and drivers of delayed care in patients undergoing surgical treatment of primary lung cancer.
First Author: Caleb Barnhill, MD


BOARD P10
Abstract 154: Design and implementation of a predictive risk model to improve oncology patient management.
First Author: Garrett Young


BOARD P11
Abstract 155: Standardizing and optimizing institutional-level documentation in the electronic medical record era.
First Author: Amy Moreno, MD, BA